Investigating Autimia, a Digital Intervention for Patients With Autism Spectrum Disorder (alnico)
Investigating Autimia, a Digital Intervention for Patients With Autism Spectrum Disorder: Randomized Controlled Trial (Alnico Trial)
The goal of this clinical trial is to find out if autimia, a digital health intervention, can help adults with ASD (Autism Spectrum Disorder) manage their daily lives and improve their well-being.
The main questions it aims to answer are:
- Does autimia, together with regular treatment, improve health outcomes after three months better than regular treatment alone?
- Are the positive effects of autimia still noticeable after six months?
Researchers will compare two groups:
- Intervention group: Participants use the autimia intervention and continue their usual treatment.
- Control group: Participants continue with their usual treatment only.
Participants will:
- Participate in a video call with a specialist to confirm a diagnosis of ASD
- Fill out questionnaires online at the start of the study, after 3 months, and after 6 months
- Continue with their usual treatment (both groups) and use autimia, a digital health intervention, for six months (intervention group only)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This pragmatic, two-arm randomized controlled trial evaluates the effectiveness of autimia, a certified medical device (CE-marked, risk class I), when used alongside regular treatment. The study compares the addition of this digital health intervention to treatment as usual (TAU) against TAU alone. Designed as an interactive online program, autimia incorporates recognized elements of cognitive behavioral therapy (CBT), behavior change, and patient education.
To ensure the inclusion of the appropriate target population, participants undergo a video-based diagnostic consultation with trained clinical professionals. This session involves a semi-structured interview and a standardized social behavior observation based on the ADOS-2 to confirm the diagnosis according to ICD-10-GM criteria.
Following confirmation, participants are randomly assigned to one of two groups. The intervention group receives immediate access to autimia for six months alongside their usual treatment. The control group continues their regular treatment and is granted access to the intervention after a six-month waiting period.
Data is collected from both groups via online questionnaires at the start of the study, after three months, and after six months. The primary evaluation of effectiveness will be conducted at the three-month follow-up. Data collected at the six-month mark will be utilized to assess the stability of the observed intervention effects.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Linda T. Betz, PhD
- Número de teléfono: +49 40 3510520
- Correo electrónico: linda.betz@gaia-group.com
Copia de seguridad de contactos de estudio
- Nombre: Anja Specht, MSc.
- Número de teléfono: +49 40 3510520
- Correo electrónico: anja.specht@gaia-group.com
Ubicaciones de estudio
-
-
-
Hamburg, Alemania
- Reclutamiento
- GAIA AG
-
Contacto:
- Anja Specht
- Correo electrónico: anja.specht@gaia-group.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- prior suspected diagnosis of ASD by a healthcare professional
- diagnosis of ASD (ICD-10 codes: F84.5, F84.0, F84.1) confirmed in a semi-structured diagnostic interview conducted as a telemedical consultation
- IQ ≥ 80
- increased levels of psychological distress (DASS-21 total score ≥ 21)
- stable treatment (medication, psychotherapy, no treatment, …) for at least 30 days at the time of inclusion
- sufficient knowledge of the German language
- basic IT skills required for independent use of a digital intervention
- consent to participation
Exclusion Criteria:
- plans to change treatment (medication, psychotherapy, …) in the upcoming 3 months after inclusion
- diagnosis of another severe psychiatric disorder (acute severe affective disorder, acute psychotic disorder, acute substance use disorder, borderline personality disorder, antisocial personality disorder)
- acute suicidality
- currently being under legal guardianship for healthcare decisions
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Grupo de control
Los participantes asignados al grupo de control recibirán acceso al tratamiento habitual (TAU).
|
|
|
Experimental: autimia
Participants will receive access to the digital health intervention autimia in addition to TAU.
|
Participants allocated to the intervention group will receive access to autimia in addition to treatment as usual (TAU). autimia is a digital health intervention designed for individuals with ASD (Autism Spectrum Disorder), accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT), health behavior change, and patient education. Topics addressed by autimia are self-acceptance and self-worth, stress management and coping skills, optimizing the environment and communication, as well as understanding emotions and social interactions. The program operates through interactive "dialogues", which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their progress. Once registered, the program remains accessible for six months. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
21-item Depression, Anxiety, and Stress Scales (DASS-21) total score
Periodo de tiempo: 3 months
|
The DASS-21 is a 21-item PROM to assess psychological distress.
The total score is the sum of all items and ranges from 0 to 63.
Higher total scores indicate greater psychological distress and thus a worse outcome, whereas lower scores indicate fewer symptoms and a better outcome.
|
3 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Work and Social Adjustment Scale (WSAS) total score
Periodo de tiempo: 3 months
|
The WSAS is a 5-item PROM to assess functional impairment in work, home life, and social activities.
The total score is the sum of all items and ranges from 0 to 40.
Higher total scores indicate greater disability and thus a worse outcome, whereas lower scores indicate less disability and a better outcome.
|
3 months
|
|
Social Responsiveness Scale for Adults (SRS-A) total score
Periodo de tiempo: 3 months
|
The SRS-A is a 65-item PROM to assess social symptomatology in adults with ASD.
The total score is the sum of all items and ranges from 0 to 195.
Higher total scores indicate greater social impairment and thus a worse outcome, whereas lower scores indicate fewer symptoms and a better outcome.
|
3 months
|
|
Multidimensional Self Esteem Scale (MSWS) emotional self-esteem subscale score
Periodo de tiempo: 3 months
|
The MSWS is a PROM to assess self-esteem.
The emotional self-esteem subscale consists of 7 items to assess emotional self-worth.
The subscale score is the sum of these items and ranges from 7 to 49. Lower scores indicate lower self-esteem and thus a worse outcome, whereas higher scores indicate higher self-esteem and a better outcome.
|
3 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Isabel Dziobek, Prof. Dr., Humboldt-Universität zu Berlin
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- autimia RCT 2026
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .